Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics

Schizophrenia Research

Volumn 176, Issue 2-3, 2016, Pages 220-230

  Misawa, Fuminari ^a,b   Kishimoto, Taishiro ^b,c,d,e   Hagi, Katsuhiko ^b,f   Kane, John M ^b,d,e,g   Correll, Christoph U ^b,d,e,g  

^a Yamanashi Prefectural University   (Japan)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^f DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Adverse events; Long acting injectable antipsychotics; Meta analysis; Oral antipsychotics; Randomized controlled trial; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; LONG ACTING INJECTABLE ANTIPSYCHOTIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PROLACTIN; RISPERIDONE; UNCLASSIFIED DRUG;

AGITATION; AKATHISIA; AKINESIA; AMENORRHEA; ANXIETY; ANXIETY DISORDER; ARTICLE; ASTHENIA; BACKACHE; BLURRED VISION; BODY WEIGHT DISORDER; CONSTIPATION; DEATH; DELIRIUM; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; DYSKINESIA; DYSMENORRHEA; DYSPHAGIA; DYSTONIA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEVER; GALACTORRHEA; HALLUCINATION; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPERSOMNIA; HYPERTENSION; HYPESTHESIA; HYPOTENSION; INCIDENCE; INJECTION SITE REACTION; INSOMNIA; LABORATORY TEST; LIBIDO DISORDER; MENSTRUATION DISORDER; META ANALYSIS; MUSCLE RIGIDITY; MUSCULOSKELETAL STIFFNESS; NAUSEA; OBSESSION; PAIN; PARESTHESIA; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RISK ASSESSMENT; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; SOMNOLENCE; SUICIDE; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TREMOR; VERTIGO; VOMITING; XEROSTOMIA; DELAYED RELEASE FORMULATION; INJECTION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; HUMANS; INJECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84995630387     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2016.07.018     Document Type: Article

References (48)

1. Adams, C.E., Fenton, M.K., Quraishi, S., David, A.S., Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br. J. Psychiatry J. Ment. Sci. 179 (2001), 290–299.
2. Alphs, L., Benson, C., Cheshire-Kinney, K., Lindenmayer, J.P., Mao, L., Rodriguez, S.C., Starr, H.L., Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J. Clin. Psychiatry 76:5 (2015), 554–561.
3. Arango, C., Bombin, I., Gonzalez-Salvador, T., Garcia-Cabeza, I., Bobes, J., Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. Eur. Psychiatry: J. Assoc. Eur. Psychiatr. 21:1 (2006), 34–40.
4. Bai, Y.M., Ting Chen, T., Chen, J.Y., Chang, W.H., Wu, B., Hung, C.H., Kuo Lin, W., Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J. Clin. Psychiatry 68:8 (2007), 1218–1225.
5. Chue, P., Eerdekens, M., Augustyns, I., Lachaux, B., Molcan, P., Eriksson, L., Pretorius, H., David, A.S., Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol. 15:1 (2005), 111–117.
6. Correll, C.U., Recognition of patients who would benefit from LAI antipsychotic treatment: how to assess adherence. J. Clin. Psychiatry, 75(11), 2014, e29.
7. Correll, C.U., The role of the extended health care team in successful LAI therapy: education to overcome barriers. J. Clin. Psychiatry, 75(9), 2014, e25.
8. del Giudice, J., Clark, W.G., Gocka, E.F., Prevention of recidivism of schizophrenics treated with fluphenazine enanthate. Psychosomatics 16:1 (1975), 32–36.
9. DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control. Clin. Trials 7:3 (1986), 177–188.
10. Detke, H.C., Weiden, P.J., Llorca, P.-M., Choukour, M.C., Watson, S.B., Brunner, E., Ascher-Svanum, H., Open-label Comparison of Olanzapine Long-acting Injection and Oral Olanzapine: A 2-year, Randomized Study in Outpatients With Schizophrenia, NCDEU 51st Annual Meeting. 2011, Boca Raton, FL.
11. Dolder, C.R., Lacro, J.P., Dunn, L.B., Jeste, D.V., Antipsychotic medication adherence: is there a difference between typical and atypical agents?. Am. J. Psychiatry 159:1 (2002), 103–108.
12. Duval, S., Tweedie, R., Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:2 (2000), 455–463.
13. Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. BMJ 315:7109 (1997), 629–634.
14. Fleischhacker, W.W., Sanchez, R., Perry, P.P., Jin, N., Peters-Strickland, T., Johnson, B.R., Baker, R.A., Eramo, A., McQuade, R.D., Carson, W.H., Walling, D., Kane, J.M., Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Brit. J. Psychiatry J. Ment. Sci. 205:2 (2014), 135–144.
15. Fusar-Poli, P., Kempton, M.J., Rosenheck, R.A., Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int. Clin. Psychopharmacol. 28:2 (2013), 57–66.
16. Haddad, P.M., Kishimoto, T., Correll, C.U., Kane, J.M., Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance. Curr. Opin. Psychiatry 28:3 (2015), 216–221.
17. Haddad, P.M., Taylor, M., Niaz, O.S., First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Brit. J. Psychiatry 52 (2009), S20–S28 (Supplement).
18. Hamann, J., Kissling, W., Heres, S., Checking the plausibility of psychiatrists arguments for not prescribing depot medication. Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol. 24:9 (2014), 1506–1510.
19. Heres, S., Long-acting injectable antipsychotics: an underutilized treatment option. J. Clin. Psychiatry 75:11 (2014), 1263–1265.
20. Heres, S., Hamann, J., Kissling, W., Leucht, S., Attitudes of psychiatrists toward antipsychotic depot medication. J. Clin. Psychiatry 67:12 (2006), 1948–1953.
21. Higgins, J.P.T., Green, S., Cochrane Handbook for Systematic Reviews of Interventions. 2011.
22. Hogarty, G.E., Schooler, N.R., Ulrich, R., Mussare, F., Ferro, P., Herron, E., Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch. Gen. Psychiatry 36:12 (1979), 1283–1294.
23. Ishigooka, J., Nakamura, J., Fujii, Y., Iwata, N., Kishimoto, T., Iyo, M., Uchimura, N., Nishimura, R., Shimizu, N., Group, A.S., Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophr. Res. 161:2–3 (2015), 421–428.
24. Kaiser, S.K., Subotnik, K.I., Ventura, J., Luo, J.S., Casaus, L.R., Turner, L.R., Hellemann, G.S., Marder, S.R., Bains, M.S., Nuechterlein, K.H., Decreased Need for Medications for Extrapyramidal Side- effects of Long-acting Injectable Risperidone After an Initial Episode of Schizophrenia, 15th International Congress on Schizophrenia Research. 2015, Colorado Springs, Colorado, USA.
25. Kamijima, K., Ishigooka, J., Komada, Y., Comparison study between risperidone long-acting injectable and risperi- done tablets in patients with schizophrenia. Jpn. J. Clin. Psychopharmacol. 12 (2009), 1199–1222.
26. Kane, J.M., Correll, C.U., Past and present progress in the pharmacologic treatment of schizophrenia. J. Clin. Psychiatry 71:9 (2010), 1115–1124.
27. Kane, J.M., Detke, H.C., Naber, D., Sethuraman, G., Lin, D.Y., Bergstrom, R.F., McDonnell, D., Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am. J. Psychiatry 167:2 (2010), 181–189.
28. Kane, J.M., Garcia-Ribera, C., Clinical guideline recommendations for antipsychotic long-acting injections. Brit. J. Psychiatry 52 (2009), S63–S67 (Supplement).
29. Kane, J.M., Kishimoto, T., Correll, C.U., Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry 12:3 (2013), 216–226.
30. Kirson, N.Y., Weiden, P.J., Yermakov, S., Huang, W., Samuelson, T., Offord, S.J., Greenberg, P.E., Wong, B.J., Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J. Clin. Psychiatry 74:6 (2013), 568–575.
31. Kishimoto, T., Nitta, M., Borenstein, M., Kane, J.M., Correll, C.U., Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J. Clin. Psychiatry 74:10 (2013), 957–965.
32. Kishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., Borenstein, M., Kane, J.M., Correll, C.U., Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr. Bull. 40:1 (2014), 192–213.
33. Lee, L.H., Choi, C., Collier, A.C., Barr, A.M., Honer, W.G., Procyshyn, R.M., The pharmacokinetics of second-generation long-acting injectable antipsychotics: limitations of monograph values. CNS Drugs 29:12 (2015), 975–983.
34. Leucht, C., Heres, S., Kane, J.M., Kissling, W., Davis, J.M., Leucht, S., Oral versus depot antipsychotic drugs for schizophrenia–a critical systematic review and meta-analysis of randomised long-term trials. Schizophr. Res. 127:1–3 (2011), 83–92.
35. Leucht, C., Heres, S., Kane, J.M., Kissling, W., Davis, J.M., Leucht, S., Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. Schizophr. Res. 127:1–3 (2011), 83–92.
36. Maayan, N., Quraishi, S.N., David, A., Jayaswal, A., Eisenbruch, M., Rathbone, J., Asher, R., Adams, C.E., Fluphenazine decanoate (depot) and enanthate for schizophrenia. Cochrane Database Syst. Rev., 2, 2015, CD000307.
37. McEvoy, J.P., Byerly, M., Hamer, R.M., Dominik, R., Swartz, M.S., Rosenheck, R.A., Ray, N., Lamberti, J.S., Buckley, P.F., Wilkins, T.M., Stroup, T.S., Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA 311:19 (2014), 1978–1987.
38. Nasrallah, H.A., The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr. Scand. 115:4 (2007), 260–267.
39. NCT00130923, Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder. ClinicalTrials.gov, 2012 https://clinicaltrials.gov/ct2/show/NCT00130923?term=NCT00130923&rank=1.
40. NCT00992407, An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder. ClinicalTrials.gov, 2014 https://clinicaltrials.gov/ct2/show/NCT00992407?term=NCT00992407&rank=1.
41. Rifkin, A., Quitkin, F., Rabiner, C.J., Klein, D.F., Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year. Arch. Gen. Psychiatry 34:1 (1977), 43–47.
42. Schooler, N.R., Levine, J., Severe, J.B., Brauzer, B., DiMascio, A., Klerman, G.L., Tuason, V.B., Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate. Arch. Gen. Psychiatry 37:1 (1980), 16–24.
43. Sheehan, J.J., Reilly, K.R., Fu, D.J., Alphs, L., Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. Innov. Clin. Neurosci. 9:7–8 (2012), 17–23.
44. Subotnik, K.L., Casaus, L.R., Ventura, J., Luo, J.S., Hellemann, G.S., Gretchen-Doorly, D., Marder, S., Nuechterlein, K.H., Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia a randomized clinical trial. JAMA Psychiatry 72:8 (2015), 822–829.
45. Starr, H.L., Mao, L., Lindenmayer, J.-P., Rodriguez, S., Alphs, L., Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE): Managing Schizophrenia Patients With a History of Incarceration and Substance Abuse, the 167th American Psychiatric Association Annual Meeting. 2014, NY, USA, New York.
46. Taylor, M., Ng, K.Y.B., Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review. Aust. N. Z. J. Psychiatry 47:7 (2013), 624–630.
47. Velligan, D.I., Wang, M., Diamond, P., Glahn, D.C., Castillo, D., Bendle, S., Lam, Y.W., Ereshefsky, L., Miller, A.L., Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr. Serv. 58:9 (2007), 1187–1192.
48. Zhornitsky, S., Stip, E., Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. Schizophr. Res. Treat., 2012, 2012, 407171.